Aiming at reversing immunosuppressive TME and overcoming ICB resistance for HCC immunotherapy, a dual pH-sensitive nanodrug was successfully developed to facilitate T cell-mediated and tumor-targeted delivery of both aPD-1 and MDK-siRNA. Here, MDK is linked to neoplasm.